Xilio Therapeutics (XLO) Free Cash Flow (QoQ) (2021 - 2026)
Xilio Therapeutics (XLO) Free Cash Flow (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.11 Bn | 1,785.05 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.57 Bn | 468.78 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.78 Bn | 116.54 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.98 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.12 Bn | 62.12 Bn | - |
| 7 | Argenx Se | 54.64 Bn | 49.45 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.05 Bn | 35.05 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.28 Bn | 36.28 Bn | - |
| 10 | Xilio Therapeutics | 148.07 Mn | -2.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,034.74% |
| Dec 31, 2025 | 88.47% |
| Sep 30, 2025 | -19.76% |
| Jun 30, 2025 | -150.92% |
| Mar 31, 2025 | 302.54% |
| Dec 31, 2024 | -3.52% |
| Sep 30, 2024 | -168.57% |
| Jun 30, 2024 | 289.61% |
| Mar 31, 2024 | 21.63% |
| Dec 31, 2023 | -0.43% |
| Sep 30, 2023 | 20.85% |
| Jun 30, 2023 | 33.56% |
| Mar 31, 2023 | -50.56% |
| Dec 31, 2022 | 16.59% |
| Sep 30, 2022 | -15.49% |
| Jun 30, 2022 | 16.89% |
| Mar 31, 2022 | -19.46% |
| Dec 31, 2021 | 12.42% |
| Sep 30, 2021 | 2.02% |
| Jun 30, 2021 | 10.17% |